financetom
Business
financetom
/
Business
/
UnitedHealth's Insurance Division CEO Brian Thompson Fatally Shot in New York
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UnitedHealth's Insurance Division CEO Brian Thompson Fatally Shot in New York
Dec 4, 2024 11:56 AM

02:37 PM EST, 12/04/2024 (MT Newswires) -- UnitedHealth Group ( UNH ) said Wednesday that Brian Thompson, chief executive of its insurance business, died, following reports that he was fatally shot in New York.

At a press conference, New York City Police Commissioner Jessica Tisch said preliminary evidence suggests that it was a targeted attack. The shooter is still at large.

"We are deeply saddened and shocked at the passing of" Thompson, UnitedHealth Group ( UNH ) wrote in a statement. "We are working closely with the New York Police Department."

Earlier in the day, the health insurer ended its annual investor conference early as a company official said "we're dealing with a very serious medical situation with one of our team members," according to a FactSet transcript.

On Tuesday, the company introduced a 2025 outlook that included sales in the $450 billion to $455 billion range. The company projected adjusted earnings per share of $29.50 to $30 in 2025.

At the time, UnitedHealth Group ( UNH ) said it continued to see 2024 adjusted EPS of $27.50 to $27.75.

Price: 609.39, Change: +4.16, Percent Change: +0.69

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Molson Coors Beverage Q3 Non-GAAP Earnings, Net Sales Decline
Molson Coors Beverage Q3 Non-GAAP Earnings, Net Sales Decline
Nov 4, 2025
06:58 AM EST, 11/04/2025 (MT Newswires) -- Molson Coors Beverage ( TAP/A ) reported Q3 non-GAAP earnings Tuesday of $1.67 per diluted share, up/down from $1.80 a year earlier. Analysts polled by FactSet expected $1.69. Net sales for the quarter ended Sept. 30 were $2.97 billion, down from $3.04 billion a year earlier. Analysts surveyed by FactSet expected $3.01 billion....
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
Nov 4, 2025
MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ( PPCB ) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced a strategic initiative to pursue the acquisition of Digital Asset Treasury (DAT) companies that are currently trading below their Market Cap to Net Asset Value (MNAV)....
PJT Partners Q3 revenue up 37%, beats estimates
PJT Partners Q3 revenue up 37%, beats estimates
Nov 4, 2025
Overview * PJT Partners ( PJT ) Q3 revenue grows 37% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting strong financial performance * Company repurchased 2.3 mln shares, indicating confidence in future growth Result Drivers * STRATEGIC ADVISORY - Increase in strategic advisory revenues drove higher Q3 revenue * FUND PLACEMENT - Increase in fund placement...
Pfizer Q3 Adjusted Earnings, Revenue Fall; Annual Adjusted EPS Outlook Upgraded
Pfizer Q3 Adjusted Earnings, Revenue Fall; Annual Adjusted EPS Outlook Upgraded
Nov 4, 2025
06:58 AM EST, 11/04/2025 (MT Newswires) -- Pfizer ( PFE ) reported Q3 adjusted earnings Tuesday of $0.87 per diluted share, down from $1.06 a year earlier. Analysts polled by FactSet expected $0.63. Revenue for the quarter was $16.65 billion, compared with $17.70 billion a year earlier. Analysts surveyed by FactSet expected $16.5 billion. The company said it now expects...
Copyright 2023-2026 - www.financetom.com All Rights Reserved